GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ludwig Enterprises Inc (OTCPK:LUDG) » Definitions » COGS-to-Revenue

Ludwig Enterprises (Ludwig Enterprises) COGS-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Ludwig Enterprises COGS-to-Revenue?

Ludwig Enterprises's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.01 Mil.

Ludwig Enterprises's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Ludwig Enterprises's Gross Margin % for the three months ended in Mar. 2024 was N/A%.


Ludwig Enterprises COGS-to-Revenue Historical Data

The historical data trend for Ludwig Enterprises's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ludwig Enterprises COGS-to-Revenue Chart

Ludwig Enterprises Annual Data
Trend Dec22 Dec23
COGS-to-Revenue
- -

Ludwig Enterprises Quarterly Data
Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial - - - - -

Ludwig Enterprises COGS-to-Revenue Calculation

Ludwig Enterprises's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

Ludwig Enterprises's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0.013
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ludwig Enterprises  (OTCPK:LUDG) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Ludwig Enterprises's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0.013
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Ludwig Enterprises COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ludwig Enterprises's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ludwig Enterprises (Ludwig Enterprises) Business Description

Traded in Other Exchanges
N/A
Address
1749 VICTORIAN AVENUE, Suite C-350, Sparks, NV, USA, 89431
Ludwig Enterprises Inc is a publicly traded Medical Technology Holding Company with Precision Genomics, Inc. and MyRNA for Life, Inc. as wholly owned subsidiaries. The company's advancements in medical technology and Artificial Intelligence (AI) have awarded it with cutting-edge genomic tools. These genomic tools have the potential to detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. It manages its business on the basis of one operating and reportable segment.